Cost-effectiveness of tiotropium versus glycopyrronium in moderate to very severe chronic obstructive pulmonary disease in Canada, Spain, Sweden, and the UK

Cost-effectiveness of tiotropium versus glycopyrronium in moderate to very severe chronic obstructive pulmonary disease in Canada, Spain, Sweden, and the UK

Oskar Eklund,1 Faraz Afzal,2 Fredrik Borgström,1 Jason Flavin,3 Andrew Ternouth,4 Maria Eugenia Ojanguren,5 Carlos Crespo,5 Mike Baldwin6 1Quantify Research AB, Stockholm, Sweden; 2Boehringer Ingelheim, Asker, Norway; 3Boehringer Ingelheim, Burlington, ON, Canada; 4Boehringer Ingelheim, Bra...

Full description

Bibliographic Details
Main Authors: Eklund O, Afzal F, Borgström F, Flavin J, Ternouth A, Ojanguren ME, Crespo C, Baldwin M
Format: Article
Language:English
Published: Dove Medical Press 2016-06-01
Series:ClinicoEconomics and Outcomes Research
Subjects:
COPD
Exacerbations
Tiotropium
Glycopyrronium
Cost-effectiveness
Markov cohort model
Online Access:https://www.dovepress.com/cost-effectiveness-of-tiotropium-versus-glycopyrronium-in-moderate-to--peer-reviewed-article-CEOR

Internet

https://www.dovepress.com/cost-effectiveness-of-tiotropium-versus-glycopyrronium-in-moderate-to--peer-reviewed-article-CEOR

Similar Items